Regional moderate hyperthermia for mild-to-moderate COVID-19 (TherMoCoV study): a randomized controlled trial

Overview of attention for article published in Frontiers in Medicine, December 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (61st percentile)

Mentioned by

twitter: 4 X users

Readers on

mendeley: 2 Mendeley

Summary X

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 12,466 followers.

RT @Abraham_RMI: Regional moderate hyperthermia for mild-to-moderate COVID-19 (TherMoCoV study): a randomized controlled trial By @Javiman…

18 Jan 2024

Reply Repost Favourite

RT @Abraham_RMI: Regional moderate hyperthermia for mild-to-moderate COVID-19 (TherMoCoV study): a randomized controlled trial By @Javiman…

18 Jan 2024

Reply Repost Favourite

Regional moderate hyperthermia for mild-to-moderate COVID-19 (TherMoCoV study): a randomized controlled trial By @Javimangal @kammarashuin et al. Via @FrontiersIn https://t.co/a5reGskIGj

17 Jan 2024

Reply Repost Favourite

8,645/ Mexico (est. current tobacco smoking age 15+ was 12.9% in 2020) Of 105 with mild-to-moderate Covid-19, 20% were smokers (not specified if current or ever) https://t.co/toUmlMUHnW

13 Jan 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.